Effect of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation

A Placebo-controlled, Randomized, Double-blind, Parallel, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03542721

Enrollment

204

Registered

2018-05-31

Start date

2018-01-17

Completion date

2019-12-31

Last updated

2018-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue Symptom

Keywords

chronic fatigue symptom, blood circulation

Brief summary

The aim of the present clinical study is to evaluate the efficacy and safety of the DA-5515 (Circulan Soft Cap.) in patients with chronic fatigue symptoms due to impaired blood circulation.

Detailed description

This study is conducting to assess the efficacy and safety of the DA-5515 (Circulan Soft Cap.), which has been known to have a fatigue recovery effect due to impaired blood circulation.

Interventions

DRUGDA-5515

Crataegi ethanol extract, Garlic oil, Ginkgo leaf extract, Melissa folium extract (three times a day)

DRUGPlacebo of DA-5515

Placebo (three times a day)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to 79 Years

Healthy volunteers

Inclusion criteria

* Rutherford's category 0/0 or Ⅰ/1 * ABI \<1.0 * CIS greater than 76 * HADS less than or equal to 10 * Subjects who have fatigue symptoms more than 1 month

Exclusion criteria

* Subjects who have diseases that can cause fatigue * Subjects who are taking medication that can cause fatigue

Design outcomes

Primary

Measure	Time frame	Description
CIS(Checklist Individual Strength) less than or equal to 76	8weeks	Rate of subjects whose CIS score has improved less than or equal to 76 at 8weeks

Countries

South Korea

Contacts

Primary ContactRan Seo

seoran@dreamwiz.com010-4547-1480

Backup ContactWhanSeok Choi

fmchs@catholic.ac.kr02-2258-6285

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026